Amphastar Pharmaceuticals (AMPH) Stock Chart - Revenue & Earnings | Quarter Chart
Revenue by Product
Revenue by Geography
Revenue, Gross Profit, Operating and Net Income
Margin (%)
Operating Expenses
EBITDA
EPS
Revenue Variation (%)
Income Variation (%)
Revenue YoY Variation (%)
Income YoY Variation (%)
Price-to-Earning Ratio
Income Breakdown
Per Share Metrics
Expense Ratios
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt Ratio
Current Ratio
Quick Ratio
Cash & Equivalents
Total Assets
Total Liabilities
Shareholders Equity
Asset Composition
Debt Structure
Amphastar Pharmaceuticals (AMPH) quarterly earnings & revenue
Amphastar Pharmaceuticals (AMPH) reported revenue of $171.17M for Q1 2026, up 0.4% year-over-year, with net income of $6.42M and diluted EPS of $0.14.
Over the last four reported quarters, Amphastar Pharmaceuticals generated $720.53M in revenue and $79.23M in net income.
Amphastar Pharmaceuticals's next earnings report is scheduled for August 6, 2026 after market close; analysts estimate EPS of $0.63.
Amphastar Pharmaceuticals quarterly results
| Fiscal quarter | Revenue | Revenue YoY | Net income | EPS (diluted) |
|---|---|---|---|---|
| Q1 2026 | $171.17M | +0.4% | $6.42M | $0.14 |
| Q4 2025 | $183.10M | -1.8% | $24.43M | $0.51 |
| Q3 2025 | $191.84M | +1.6% | $17.35M | $0.37 |
| Q2 2025 | $174.41M | -4.4% | $31.03M | $0.64 |
| Q1 2025 | $170.53M | -0.8% | $25.29M | $0.51 |
| Q4 2024 | $186.52M | +4.7% | $37.96M | $0.74 |
| Q3 2024 | $188.82M | +4.6% | $40.43M | $0.78 |
| Q2 2024 | $182.39M | +25.2% | $37.95M | $0.73 |
Amphastar Pharmaceuticals (AMPH) — frequently asked questions
When does Amphastar Pharmaceuticals (AMPH) report earnings next?
Amphastar Pharmaceuticals is expected to report earnings on August 6, 2026 after market close. Analysts estimate EPS of $0.63.
What was AMPH's revenue last quarter?
Amphastar Pharmaceuticals reported revenue of $171.17M in Q1 2026, up 0.4% from the same quarter a year earlier.
What was AMPH's EPS last quarter?
Amphastar Pharmaceuticals reported diluted EPS of $0.14 in Q1 2026.
Is Amphastar Pharmaceuticals profitable?
Amphastar Pharmaceuticals is currently profitable, with $79.23M in net income over the last four reported quarters.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)